Clinical Research Directory
Browse clinical research sites, groups, and studies.
SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis
Sponsor: Ruijin Hospital
Summary
This study is a prospective, randomized, two-cohort trial designed to evaluate the efficacy and safety of two regimens in the treatment of gastric or gastroesophageal junction adenocarcinoma with peritoneal metastasis: SHR-1701 combined with intravenous and intraperitoneal paclitaxel plus S-1, or SHR-1701 combined with CAPOX.
Official title: SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: A Randomized, Two-Cohort Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-01-31
Completion Date
2030-12-30
Last Updated
2026-02-03
Healthy Volunteers
No
Interventions
SHR-1701
SHR-1701, 1800mg, Q3w
Capecitabine
Capecitabine, Q3W
S-1
S-1, Q3W
Paclitaxel
Paclitaxel,Q3W
Oxaliplatin
Oxaliplatin, Q3W
Locations (2)
Changhai Hospital
Shanghai, Shanghai Municipality, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China